

1. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. *Ann Intern Med*. 2017 Sep 5;167(5):293–301.
2. Ahrnsbrak R. Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. 2016;86.
3. Williams AR, Nunes EV, Bisaga A, Pincus HA, Johnson KA, Campbell AN, et al. Developing an opioid use disorder treatment cascade: A review of quality measures. *J Subst Abuse Treat*. 2018 Aug;91:57–68.
4. Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. *Proc Natl Acad Sci U S A*. 2015 Dec 8;112(49):15078–83.
5. Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. *NCHS Data Brief*. 2018 Nov;(328):1–8.
6. Hedegaard H, Miniño AM, Warner M. Drug Overdose Deaths in the United States, 1999-2017. *NCHS Data Brief*. 2018 Nov;(329):1–8.
7. Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, et al. County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States. *J Acquir Immune Defic Syndr* 1999. 2016 01;73(3):323–31.
8. Reported Law Enforcement Encounters Testing Positive for Fentanyl Increase Across US | Drug Overdose | CDC Injury Center [Internet]. [cited 2019 Apr 17]. Available from: <https://www.cdc.gov/drugoverdose/data/fentanyl-le-reports.html>
9. Agarwal SD, Landon BE. Patterns in Outpatient Benzodiazepine Prescribing in the United States. *JAMA Netw Open*. 2019 Jan 4;2(1):e187399.
10. Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. *BMJ*. 2017 Mar 14;356:j760.
11. NCHS Data Visualization Gallery - Drug Poisoning Mortality [Internet]. 2019 [cited 2019 Apr 17]. Available from: <https://www.cdc.gov/nchs/data-visualization/drug-poisoning-mortality/index.htm>
12. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. *Mt Sinai J Med N Y*. 2000 Nov;67(5–6):347–64.
13. Longshore D, Hsieh S, Danila B, Anglin MD. Methadone maintenance and needle/syringe sharing. *Int J Addict*. 1993 Aug;28(10):983–96.
14. Corsi KF, Lehman WK, Booth RE. The effect of methadone maintenance on positive outcomes for opiate injection drug users. *J Subst Abuse Treat*. 2009 Sep;37(2):120–6.
15. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database Syst Rev*. 2009 Jul 8;(3):CD002209.

16. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev.* 2014 Feb 6;(2):CD002207.
17. Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. *Cochrane Database Syst Rev.* 2016 May 9;(5):CD011117.
18. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. *JAMA.* 2000 Mar 8;283(10):1303–10.
19. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. *J Subst Abuse Treat.* 2005 Jun;28(4):321–9.
20. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. *Cochrane Database Syst Rev.* 2003;(3):CD002208.
21. Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. *BMJ.* 2010 Jul 1;341:c3172.
22. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. *BMJ.* 2010 Oct 26;341:c5475.
23. Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. *JAMA Intern Med.* 2014 Dec;174(12):1947–54.
24. Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. *Arch Gen Psychiatry.* 2011 Dec;68(12):1238–46.
25. Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and Treatment of Opioid Misuse and Addiction: A Review. *JAMA Psychiatry.* 2019 Feb 1;76(2):208–16.
26. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. *Lancet Lond Engl.* 2003 Feb 22;361(9358):662–8.
27. Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. *Ann Fam Med.* 2015 Feb;13(1):23–6.
28. Knudsen HK. The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis. *J Stud Alcohol Drugs.* 2015 Jul;76(4):644–54.
29. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. *Lancet Lond Engl.* 2011 Apr 30;377(9776):1506–13.

30. Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, et al. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. *N Engl J Med*. 2016 Mar 31;374(13):1232–42.
31. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. *Arch Gen Psychiatry*. 2006 Feb;63(2):210–8.
32. Nunes EV, Krupitsky E, Ling W, Zummo J, Memisoglu A, Silverman BL, et al. Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond? *J Addict Med*. 2015 Jun;9(3):238–43.
33. Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. *Addict Abingdon Engl*. 2013 Sep;108(9):1628–37.
34. Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. *Lancet Lond Engl*. 2018 27;391(10118):309–18.
35. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. *Ann Intern Med*. 2018 Aug 7;169(3):137–45.
36. Schwartz RP, Gryczynski J, O’Grady KE, Sharfstein JM, Warren G, Olsen Y, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. *Am J Public Health*. 2013 May;103(5):917–22.
37. Clausen T, Waal H, Thoresen M, Gossop M. Mortality among opiate users: opioid maintenance therapy, age and causes of death. *Addict Abingdon Engl*. 2009 Aug;104(8):1356–62.
38. Board TE. Opinion | Want to Reduce Opioid Deaths? Get People the Medications They Need. *The New York Times* [Internet]. 2019 Mar 27 [cited 2019 Apr 17]; Available from: <https://www.nytimes.com/2019/03/26/opinion/opioid-crisis-sacklers-purdue.html>
39. Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. *Lancet Lond Engl*. 2019 Mar 13;
40. Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O’Grady KE, Schwartz RP. Update on Barriers to Pharmacotherapy for Opioid Use Disorders. *Curr Psychiatry Rep*. 2017 Jun;19(6):35.
41. Saleh SS, Vaughn T, Hall J, Levey S, Fuortes L, Uden-Holmen T. Effectiveness of case management in substance abuse treatment. *Care Manag J J Case Manag J Long Term Home Health Care*. 2002;3(4):172–7.
42. Day CA, Demirkol A, Tynan M, Curry K, Hines S, Lintzeris N, et al. Individual versus team-based case-management for clients of opioid treatment services: an initial evaluation of what clients prefer. *Drug Alcohol Rev*. 2012 Jun;31(4):499–506.
43. Plater-Zyberk CJ, Varenbut M, Daiter J, Worster A. The value of clinical case management in a methadone maintenance treatment program. *Am J Drug Alcohol Abuse*. 2012 Jan;38(1):70–2.

44. Strathdee SA, Ricketts EP, Huettner S, Cornelius L, Bishai D, Havens JR, et al. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial. *Drug Alcohol Depend.* 2006 Jul 27;83(3):225–32.
45. Stein MD, Anderson B. Injection frequency mediates health service use among persons with a history of drug injection. *Drug Alcohol Depend.* 2003 May 21;70(2):159–68.
46. Rockett IRH, Putnam SL, Jia H, Smith GS. Assessing substance abuse treatment need: a statewide hospital emergency department study. *Ann Emerg Med.* 2003 Jun;41(6):802–13.
47. Bernstein E, Bernstein J, Levenson S. Project ASSERT: an ED-based intervention to increase access to primary care, preventive services, and the substance abuse treatment system. *Ann Emerg Med.* 1997 Aug;30(2):181–9.
48. Rockett IRH, Putnam SL, Jia H, Chang CF, Smith GS. Unmet substance abuse treatment need, health services utilization, and cost: a population-based emergency department study. *Ann Emerg Med.* 2005 Feb;45(2):118–27.
49. Weinstein ZM, Wakeman SE, Nolan S. Inpatient Addiction Consult Service: Expertise for Hospitalized Patients with Complex Addiction Problems. *Med Clin North Am.* 2018 Jul;102(4):587–601.
50. Shanahan CW, Beers D, Alford DP, Brigandi E, Samet JH. A transitional opioid program to engage hospitalized drug users. *J Gen Intern Med.* 2010 Aug;25(8):803–8.
51. Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. *JAMA Intern Med.* 2014 Aug;174(8):1369–76.
52. Sorensen JL, Masson CL, Delucchi K, Sporer K, Barnett PG, Mitsuishi F, et al. Randomized trial of drug abuse treatment-linkage strategies. *J Consult Clin Psychol.* 2005 Dec;73(6):1026–35.
53. Carroll KM, Weiss RD. The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review. *Am J Psychiatry.* 2017 01;174(8):738–47.
54. DiClemente CC, Corno CM, Graydon MM, Wiprovnick AE, Knoblach DJ. Motivational interviewing, enhancement, and brief interventions over the last decade: A review of reviews of efficacy and effectiveness. *Psychol Addict Behav J Soc Psychol Addict Behav.* 2017;31(8):862–87.
55. Coffin PO, Santos G-M, Matheson T, Behar E, Rowe C, Rubin T, et al. Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: A pilot randomized controlled trial. *PloS One.* 2017;12(10):e0183354.
56. Thakarar K, Weinstein ZM, Walley AY. Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist. *Postgrad Med J.* 2016 Jun;92(1088):356–63.
57. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. *BMJ.* 2013 Jan 30;346:f174.

58. Levin FR, Bisaga A, Sullivan MA, Williams AR, Cates-Wessel K. A review of a national training initiative to increase provider use of MAT to address the opioid epidemic. *Am J Addict*. 2016;25(8):603–9.
59. Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. *N Engl J Med*. 2006 Jul 27;355(4):365–74.
60. Brooklyn JR, Sigmon SC. Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact. *J Addict Med*. 2017 Aug;11(4):286–92.
61. LaBelle CT, Han SC, Bergeron A, Samet JH. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers. *J Subst Abuse Treat*. 2016 Jan;60:6–13.
62. Komaromy M, Duhigg D, Metcalf A, Carlson C, Kalishman S, Hayes L, et al. Project ECHO (Extension for Community Healthcare Outcomes): A new model for educating primary care providers about treatment of substance use disorders. *Subst Abuse*. 2016;37(1):20–4.
63. D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. *JAMA*. 2015 Apr 28;313(16):1636–44.
64. D'Onofrio G, Chawarski MC, O'Connor PG, Pantalon MV, Busch SH, Owens PH, et al. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention. *J Gen Intern Med*. 2017 Jun;32(6):660–6.
65. Powell KG, Treitler P, Peterson NA, Borys S, Hallcom D. Promoting opioid overdose prevention and recovery: An exploratory study of an innovative intervention model to address opioid abuse. *Int J Drug Policy*. 2019 Feb;64:21–9.